R. J Thorac Oncol 2010, 5:34-38. 145. Sullivan Pepe M, Etzioni R, Feng – Frisk

R. J Thorac Oncol 2010, 5:34-38. 145. Sullivan Pepe M, Etzioni R, Feng

Exclusive Chauffeur Service At Nice Airport
23 diciembre, 2021
23 diciembre, 2021

R. J Thorac Oncol 2010, 5:34-38. 145. Sullivan Pepe M, Etzioni R, Feng

R. J Thorac Oncol 2010, 5:34-38. 145. Sullivan Pepe M, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y: Phases of biomarker growth for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061. 146. Warner E, Jotkowitz A, Maimon N: Lung cancer screening re we there but? Eur J Intern Med 2010, 21:6-11. 147. Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanche JP, Confavreux C, Vighetto A, Renault-Mannel V, Michel D, Honnorat J: [18F] fluorodeoxyglucose positron emission tomography from the diagnosis of cancer in clients with paraneoplastic neurological syndrome and antiHu antibodies. Ann Neurol 2000, forty eight:105-108. 148. Henschke CI, Yankelevitz DF, Naidich DP, McCauley DI, McGuinness G, Libby DM, Smith JP, Pasmantier MW, Miettinen OS: CT screening for lung cancer: suspiciousness of nodules in accordance to dimensions on baseline scans. Radiology 2004, 231:164-168. 149. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Omeprazole sodium Koizumi J, Altorki NK, Smith JP: Early Lung Most cancers Motion Venture: in general design and style and results from baseline screening. Lancet 1999, 354:99-105. a hundred and fifty. Henschke CI, Naidich DP, Yankelevitz DF, McGuinness G, McCauley DI, Smith JP, Libby D, Pasmantier M, Vazquez M, Koizumi PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/16570919 J, Flieder D, Altorki N, Miettinen OS: Early lung most cancers action venture: original conclusions on repeat screenings. Cancer 2001, 92:153-159. 151. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS: Survival of patients with phase I lung most cancers detected on CT screening. N Engl J Med 2006, 355:1763-1771. 152. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB: Computed tomography screening and lung cancer outcomes. JAMA 2007, 297:953-961. 153. Jett JR: Limits of screening for lung cancer with low-dose spiral computed tomography. Clin Cancer Res 2005, eleven:4988s-4992s. 154. Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM, Aughenbaugh GL, Zink FE, Hillman SL, Noetzel GR, Marks RS, Clayton AC, Pairolero Computer: Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Treatment Med 2002, a hundred sixty five:508-513. one hundred fifty five. Anglim PP, Alonzo TT, Laird-Offringa IA: DNA methylation-based biomarkers for early detection of non-small cell lung most cancers: an update. Mol Cancer 2008, seven:eighty one. 156. Bach PB, Silvestri GA, Hanger M, Jett JR: Screening for lung most cancers: ACCP evidence-based medical observe pointers (2nd edition). Upper body 2007, 132:69S-77S. 157. Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ: The Countrywide Lung Screening Trial: overview and research style. Radiology 2011, 258:243-253. 158. Anderson KS, LaBaer J: The sentinel in just: exploiting the immune program for cancer biomarkers. J Proteome Res 2005, 4:1123-1133. 159. Averbeck M, Gebhardt C, Emmrich F, Treudler R, Simon JC: Immunologic rules of allergic disorder. J Dtsch Dermatol Ges 2007, five:1015-1028. one hundred sixty. Lu H, Goodell V, Disis ML: Humoral immunity directed from tumorassociated antigens as prospective biomarkers for that early analysis of cancer. J Proteome Res 2008, 7:1388-1394. 161. Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y, Abu-Shakra M, Barzilai O, Berkun Y, Blank M, de Carvalho JF, Doria A, Gilburd B, Katz U, Krause I, Langevitz P, Orbach H, Pordeus V, Ram M,Kazarian and Laird-.


¿Olvidaste la contraseña?

Shopping cart
Aún no agregaste productos.
Seguir viendo